Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections
Whittle, Emma , Jeraldo, Patricio , Nelson, Heidi , Kendrick, Michael L. , Patel, Robin , Truty, Mark J. , Yonkus, Jennifer A. , Jeraldo, Patricio R , Alva-Ruiz, Roberto, Grys, Thomas E. , Patel, Robin , Alva‐Ruiz, Roberto , Chia, Nicholas

Mayo Clinic

mSphere | February 16, 2022 | Volume: 7 | Issue: 1 | Pages: No page available

10.1128/msphere.00964-21 | PMID 35171692 Get It

Surgical site infections (SSI) are a significant burden to patients and health care systems. They increase mortality rates, length of hospital stays, and associated health care costs.
Accuracy of Simulated Research Tasks by Community Hospitals Participating in a Multicenter Telemedicine Trial
Fang, Jennifer L. , Whyte, Hilary, Umoren, Rachel , Limjoco, Jamie , Yankanah, Rosanna, McCoy, Mike, Lo, Mark D., Demaerschalk, Bart M. , Demaerschalk, Bart M , Makkar, Abhishek , Herrin, Jeph

Mayo Clinic

Telemedicine and e-Health | February 15, 2022 | Volume: 28 | Issue: 10 | Pages: 1489-1495

10.1089/tmj.2021.0574 | PMID 35167373 Get It

Background/Aims: Clinical trials evaluating facility-to-facility telemedicine may include sites that have limited research experience. For the trial to be successful, these sites must correctly perform research-related tasks. This study aimed to determine whether health care professionals at community hospitals could accurately identify simulated study eligible patients and submit data to a research coordinating center. Methods: Twenty-seven community hospitals in the United States and Canada participated in this study. An electronic survey was sent to one designated health care professional at each site. The survey included a description of trial eligibility criteria and five written neonatal resuscitation scenarios. For each scenario, the participant determined whether the neonate was study eligible. One scenario required participants to submit 14 data elements to the coordinating center. Accuracy of study eligibility and data submission was summarized using standard descriptive statistics. Results: The survey response rate was 100% (27/27). Overall accuracy in determining study eligibility was 89% (120/135), and accuracy varied across the five scenarios (range 82–93%). Overall accuracy of data submission was 92% (310/336). Data were >95% accurate for 9 of the 14 data elements, with 100% accuracy achieved for 6 data elements. These results were used to clarify eligibility criteria, inform database design, and improve training materials for the subsequent clinical trial. Conclusions: Health care professionals at community hospitals accurately determined trial eligibility and submitted study data based on written clinical scenarios. Research teams conducting telemedicine trials with community hospitals should consider completing pre-trial simulation activities to identify opportunities for improving trial processes and materials.
Reimagining Learning Spaces of the Future: An Interprofessional, Virtual Workshop Utilizing Rapid Idea Generation and Lean Startup Methodologies
Billings, Heather , Malin, Theresa, Bergene, Angela, Cornelius, Katherine , Craft, Stacy, Hartzheim, Lisa, Johnson, Stacy A., Kallay, Jennifer, Kreuter, Justin D. , Raths, Michelle, Renner, Amy Seegmiller , Hall, Elissa , Allen, Jennifer, Kreuter, Justin, Billings, Heather , Cornelius, Katherine E , Allen, Jennifer

Mayo Clinic

MedEdPORTAL | February 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11217 | PMID 35224186 Get It

Eye Movement Desensitization and Reprocessing in a Primary Care Setting: Assessing Utility and Comparing Efficacy of Virtual Versus In-Person Methods
Liou, Harris , Lane, Colton, Huang, Crystal , Mookadam, Martina , Joseph, Malin, DuVal, Jennifer Hecker, Hecker DuVal, Jennifer

Mayo Clinic

Telemedicine and e-Health | February 8, 2022 | Volume: 28 | Issue: 9 | Pages: 1359-1366

10.1089/tmj.2021.0454 | PMID 35133887 Get It

Introduction: Eye movement desensitization and reprocessing (EMDR) is an evidence-based psychotherapy method designed to treat distress associated with traumatic memories. The COVID-19 pandemic has challenged providers to shift EMDR to telehealth platforms. Objectives: This research had to aims. (1) To compare EMDR in conjunction with cognitive behavioral therapy (CBT) with CBT alone for treatment of a patient population with prevalent anxiety and (2) to compare the efficacy of virtual EMDR with that of in-person EMDR in the primary care setting. Methods: Retrospective chart review of all adult patients seen by a single therapist at a primary care center was conducted from January 2018 to December 2020. Charts were reviewed for demographics, psychiatric diagnoses, number of visits, number and type of EMDR treatments, and patient health questionnaire (PHQ)-9 and general anxiety disorder (GAD-7) scores pre- and post-treatment. Results: Patients who underwent EMDR with CBT demonstrated greater decreases in PHQ-9 and GAD-7 scores than patients who had only CBT (2.4, 2.5 vs. 0.9, 1.1). However, after adjusting for total number of sessions, post-traumatic stress disorder, grief, and pain, the adjusted mean differences of change in PHQ-9 and GAD-7 scores between those who underwent EMDR with CBT and CBT-exclusive patients were not statistically significant. Similarly, the adjusted mean differences of change in PHQ-9 and GAD-7 scores between those who underwent virtual EMDR and those who had in-person EMDR were not statistically significant. Conclusions: To our knowledge, this is the first study describing the use of virtual EMDR in a primary care setting. Although our data did not provide evidence for the superiority of EMDR with CBT over CBT alone, we demonstrate that both in-person and virtual EMDR led to significantly improved GAD-7 scores.
Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies
Doubeni, Chyke A. , Pennello, Gene , Carlson, Robert W. , Lau, Yan Kwan, Pennello, Gene A , Carlson, Robert W , Lau, Yan Kwan , Lin, Jennifer S , Doubeni, Chyke A.

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 883-891

10.1002/cncr.33954 | PMID 35133658 Get It

Multicancer screening is a promising approach to improving the detection of preclinical disease, but current technologies have limited ability to identify precursor or early stage lesions, and approaches for developing the evidentiary chain are unclear. Frameworks to enable development and evaluation from discovery through evidence of clinical effectiveness are discussed.
Consensus Recommendation for Mouse Models of Ocular Hypertension to Study Aqueous Humor Outflow and Its Mechanisms
McDowell, Colleen M , Kizhatil, Krishnakumar , Elliott, Michael H. , Overby, Darryl R. , Sherwood, Joseph M. , Millar, J. Cameron , Kuehn, Markus H. , Zode, Gulab , Acott, Ted S. , Anderson, Michael G. , Bertrand, Jacques, Borrás, Terete, Bovenkamp, Diane E. , Cheng, Lin , Danias, John, Ieso, Michael L. De , Du, Yiqin , Faralli, Jennifer A., Fuchshofer, Rudolf , Ganapathy, Preethi S. , Gong, Haiyan , Hernandez, Humberto , John, Simon W. M. , Kaufman, Paul L., Keller, Kate E. , Kelley, Mary J. , Kelly, Ruth A. , Križaj, David , Kumar, Ajay , Leonard, Brian C. , Liu, Katy C., López, Navita N., Mao, Weiming , Mavlyutov, Timur, McDonnell, Fiona , Mzyk, Philip , Nartey, Andrews , Pasquale, Louis R. , Patel, Gaurang , Pattabiraman, Padmanabhan P. , Peters, Donna M. , Raghunathan, Vijaykrishna, Rao, Ponugoti Vasantha , Rayana, Naga Pradeep , Raychaudhuri, Urmimala, Reina‐Torres, Ester , Rhee, Douglas J. , Chowdhury, Uttio Roy, Samples, John R., Samples, E. Griffen, Sharif, Najam A. , Schuman, Joel S. , Stevenson, Cooper H., Soundararajan, Avinash , Subramanian, Preeti, Sugali, Chenna Kesavulu , Sun, Yang , Torrejon, Karen Y., Vahabikashi, Amir , Vranka, Janice A., Wang, Ting , Willoughby, Colin E. , Chen, Xin , Yun, Hongmin , Fautsch, Michael P. , Tamm, Ernst R. , Clark, Abbot F. , Ethier, C. Ross , Schuman, Joel S , Bhattacharya, Sanjoy K. , Bertrand, Jacques A., Herberg, Samuel , Humphries, Peter , Lieberman, Raquel L. , Liton, Paloma B. , Liu, Yutao , McLellan, Gillian J. , Raghunathan, Vijay Krishna , Rao, Ponugoti Vasantha , Ren, Ruiyi , Sheffield, Val C. , Toris, Carol B. , Zhang, Hao F. , Stamer, William Daniel

Mayo Clinic

Investigative Opthalmology & Visual Science | February 7, 2022 | Volume: 63 | Issue: 2 | Pages: 12

10.1167/iovs.63.2.12 | PMID 35129590 Get It

Research Goes Red: Early Experience With a Participant-Centric Registry
Gilchrist, Susan C. , Hall, Jennifer L. , Khandelwal, Abha , Hidalgo, Bertha , Kinzy, Claire, Mallya, Pratheek , Conners, Katie, Stevens, Laura , Alger, Heather M. , Wexler, Laura, Mega, Jessica L. , Mieres, Jennifer H. , Roger, Véronique L. , Stevens, Laura M , Alger, Heather M , Mehta, Laxmi , Hernandez, Adrian , Hayes, Sharonne N , Jessup, Mariell , Roger, Veronique L , Hall, Jennifer L , Aggarwal, Brooke , Mehta, Laxmi S. , Hernandez, Adrian F. , Hayes, Sharonne N.

Mayo Clinic

Circulation Research | February 3, 2022 | Volume: 130 | Issue: 3 | Pages: 343-351

10.1161/circresaha.121.320403 | PMID 35113661 Get It

Rationale: Cardiovascular disease remains the leading cause of death in women. To address its determinants including persisting cardiovascular risk factors amplified by sex and race inequities, novel personalized approaches are needed grounded in the engagement of participants in research and prevention. Objective: To report on a participant-centric and personalized dynamic registry designed to address persistent gaps in understanding and managing cardiovascular disease in women. Methods and Results: The American Heart Association and Verily launched the Research Goes Red registry (RGR) in 2019, as an online research platform available to consenting individuals over the age of 18 years in the United States. RGR aims to bring participants and researchers together to expand knowledge by collecting data and providing an open-source longitudinal dynamic registry for conducting research studies. As of July 2021, 15 350 individuals have engaged with RGR. Mean age of participants was 48.0 48.0±0.2 years with a majority identifying as female and either non-Hispanic White (75.7%) or Black (10.5%). In addition to 6 targeted health surveys, RGR has deployed 2 American Heart Association-sponsored prospective clinical studies based on participants’ areas of interest. The first study focuses on perimenopausal weight gain, developed in response to a health concerns survey. The second study is designed to test the use of social media campaigns to increase awareness and participation in cardiovascular disease research among underrepresented millennial women. Conclusions: RGR is a novel online participant-centric platform that has successfully engaged women and provided critical data on women’s heart health to guide research. Priorities for the growth of RGR are centered on increasing reach and diversity of participants, and engaging researchers to work within their communities to leverage the platform to address knowledge gaps and improve women’s health.
Abstract TP201: How Often Is Occult Atrial Fibrillation In Cryptogenic Stroke Causal Versus Incidental?
Chaisinanunkul, Napasri , Fugate, Jennifer E. , Khurshid, Shaan , Buck, Brian , Rabinstein, Alejandro A. , Anderson, Christopher D. , Hill, Michael D. , Saver, Jeffrey L.

Mayo Clinic

Stroke | February 3, 2022 | Volume: 53 | Issue: Suppl_1 | Pages: No page available

10.1161/str.53.suppl_1.tp201 Get It

Introduction: Long-term cardiac monitoring studies have unveiled low-burden, occult atrial fibrillation (AF) in some patients with otherwise cryptogenic stroke (CS). But occult AF is also found in some normal individuals and patients with stroke of known cause (KS). Clinical management would be aided by estimates of how often occult AF in a patient with CS is causal versus incidental. Methods: Through systematic search, we identified all case-control and cohort studies applying identical long-term monitoring techniques to both CS and KS patients. We performed a random-effects meta-analyses across these studies to determine the best estimate of the differential frequency of occult AF in CS and KS among all patients, and across age subgroups. We then applied Bayes’ theorem (method of Alsheikh-Ali et al, Stroke 2009) to determine the probability that occult AF is causal or incidental. Results: The systematic search identified 3 case-control and cohort studies enrolling 575 patients (337 CS, 238 KS). Methods of long-term monitoring were implantable loop recorder in 191 (33.2%), extended mobile external cardiac monitor in 277 (48.2%), and patch/event/Holter monitoring in 107 (18.6%). In formal meta-analysis, the summary odds ratio for occult AF in CS vs KS in all patients was 1.72 (95%CI 0.91-3.25) (Figure). With application of Bayes theorem, the corresponding probabilities indicated that, when present, occult AF in CS patients is causal in 44.4% and incidental in 55.6%. Only one study reported age-specific subgroup data: these suggested occult AF in CS patients was causal in 93% of patients <65y vs 5.6% of patients ≥65y, but estimates had limited precision. Conclusions: In patients with cryptogenic stroke, when occult AF is found, it is likely causal in about 44% of patients, who may benefit from anticoagulation, and likely incidental in about 56% of patients, who may not benefit from anticoagulation. Figure
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study
Josephs, Keith A. , Weigand, Stephen D. , Whitwell, Jennifer L. , ADNI, ADNI

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.056124 Get It

AbstractBackgroundDiagnosing Alzheimer’s disease (AD) with biomarkers requires evidence of abnormal beta‐amyloid (Aβ) and tau. Individuals that are Aβ‐positive, but tau‐negative, are considered to have AD neuropathologic change, or early AD. The objective of this study was to determine whether some Aβ‐positive but tau‐negative individuals remain tau‐negative 5‐years later and describe the characteristics of such individuals.MethodWe identified 45 individuals from ADNI who were Aβ‐positive but tau‐negative on PET more than five years after their first abnormal Aβ‐PET (Amyloid+ Low Tau, ALT group). For comparison, we identified 157 Aβ‐positive individuals that had abnormal tau‐PET within five years of their first abnormal Aβ‐PET (i.e. biomarker‐AD). Aβ‐positivity was determined by ADNI‐provided cut‐points of 1.11 for AV45 and 1.08 for florbetapir. A negative tau‐PET scan was defined using Gaussian mixture modeling.ResultThe ALT and biomarker‐AD groups were similar in terms of sex and age at the time of their first Aβ‐PET scan. However, the ALT group was characterized by a lower proportion of APOE ε4 carriers (31% versus 67%, p<0.001), a lower median centiloid (36 versus 85, p<0.001, Figure) and lower likelihood of having a dementia diagnosis at first Aβ PET (2% versus 22%, p<0.001) compared to the biomarker‐AD group. The ALT group also performed better on tests of general cognition and had larger hippocampal volume compared to biomarker‐AD (p<0.001 for all). APOE ε4 status, centiloid and hippocampal volume were all associated with increased odds of elevated tau within 5 years from baseline Aβ‐PET (Table). Within the ALT group, 19 (42%) had high centiloid (>40): these individuals did not differ from the <40 centiloid individuals in clinical diagnosis, but there was some indication of a higher APOE ε4 frequency (42% versus 23%; p=0.30).ConclusionAmyloid‐positive individuals can remain tau‐negative for at least five years, and without becoming demented. Baseline characteristics can help identify these ALT individuals that have a low risk of progression. These findings beg the question of whether more conservative Aβ cut‐points are required for diagnosis of individuals with a high risk of developing AD.
Relationship of APOE, age, amyloid and clinical phenotype in Alzheimer disease
Whitwell, Jennifer L. , Tosakulwong, Nirubol , Weigand, Stephen D. , Graff‐Radford, Jonathan , Ertekin‐Taner, Nilüfer , Lowe, Val J. , Josephs, Keith A. , ADNI, Machulda, Mary M. , Duffy, Joseph R. , Senjem, Matthew L. , Jack, Clifford R. , ADNI

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.055086 Get It

AbstractBackgroundThe apolipoprotein ε4 (APOE4) allele is the most common and well established risk factor for typical late‐onset amnestic Alzheimer’s dementia. Less is known about the role of APOE in patients with atypical clinical presentations of AD, with studies often disagreeing on APOE4 frequencies in these cohorts. We aimed to assess relationships between APOE genotype and age, amyloid‐beta (Aβ) deposition and clinical phenotype in Alzheimer’s disease.Method138 atypical AD patients (57 posterior cortical atrophy and 81 logopenic aphasia) were recruited by the Neurodegenerative Research Group at Mayo Clinic, and underwent APOE testing and Pittsburgh Compound B PET. 318 typical AD patients with APOE genotype and known onset age were identified from ADNI (121 had Aβ‐PET). Aβ‐PET was quantified using the centiloid scale. Logistic regression was used to estimate the proportion of APOE4 carriers by onset age and clinical group. Linear regression was used to estimate mean Aβ centiloid by age, APOE4 status, and clinical group in patients who were Aβ‐positive (centiloid≥19).ResultThe overall frequency of APOE4 carriers was lower in atypical AD (52%) compared to typical AD (66%), particularly for ε4ε4 homozygotes (9% vs 20%). APOE4 frequency increased with age in atypical AD, but showed a bell‐shaped curve in typical AD where highest frequencies were observed between 65‐70 years (Figure). Typical AD showed higher APOE4 frequencies than atypical AD only between the ages of 57 and 69 years. Aβ centiloid was higher in atypical AD compared to typical AD by approximately 16 centiloid units, but did not differ according to APOE4 status (Figure). Aβ centiloid stayed relatively flat with increasing age for both carriers and non‐carriers in atypical AD, but declines with increasing age in typical AD. Relationships between APOE4 and age, as well as centiloid, did not differ between the two atypical AD phenotypes.ConclusionAPOE4 frequency differs between atypical and typical AD but is highly dependent upon age, with higher APOE4 frequency in typical AD only observed between 57 and 69 years. The findings highlight the importance of age and clinical phenotype in understanding the effects of APOE genotype in Alzheimer’s disease.